Morris Laster, MD is Co-Founder and CEO of Metabolize, a pre-seed nutraceutical company pioneering metabolite-driven solutions to address post-GLP-1 weight rebound and long-term metabolic health.

A medical doctor trained at Downstate Health Sciences University, Dr. Laster has built a 30-year career as a biomedical entrepreneur and investor across the US and Israel.

Dr. Laster secured an exclusive worldwide license from Stanford University's Office of Technology Licensing for two proprietary metabolites developed in Dr. Jonathan Long's lab, forming the scientific core of Metabolize.

He has founded 6 companies that have gone public in the US, UK, and Israel, including Kitov Pharmaceuticals (FDA-approved drug Consensi), BioLineRx, and Keryx Biopharmaceuticals (NASDAQ: KERX), and served as Medical Venture Partner at OurCrowd leading 28 investments.

Metabolize's lead products NatLean and MetaPair target the growing post-GLP-1 consumer health market, with animal studies showing close to 30% reductions in key metabolic markers such as glucose, triglycerides, and cholesterol, backed by SOSV and IndieBio.